Marc P. Bonaca, MD, MPH

Marc Bonaca, MD, MPH | Image Credit: Novo Nordisk

Marc Bonaca, MD, MPH, is the executive director at CPC Clinical Research, director of vascular research at the University of Colorado Anschutz, and a cardiologist with Brigham and Women’s Hospital and the VA Boston Healthcare System.

Articles by Marc P. Bonaca, MD, MPH

VESALIUS-CV: Evolocumab Prevents Cardiovascular Disease in High-Risk Diabetes

ByMarc P. Bonaca, MD, MPH

August 7th 2026

The phase 3 trial of evolocumab showed cardioprotective effects in patients without prior MI or stroke, regardless of qualifying atherosclerosis or background therapy.

Semaglutide Boosts PAD Outcomes in STRIDE with Marc P. Bonaca, MD, MPH

ByMarc P. Bonaca, MD, MPH

April 3rd 2025

Marc Bonaca, MD, MPH, examines the benefit of semaglutide on functional outcomes in PAD from the STRIDE trial at ACC.25.

Navigating Lifestyle and Pharmacotherapy Interventions in Dyslipidemia Management

ByPam R. Taub, MD, FACC, FASPC ,Marc P. Bonaca, MD, MPH

December 23rd 2024

Panelists discuss how lifestyle interventions, including diet, physical activity, and smoking cessation, complement pharmacotherapy in the management of dyslipidemia, and explore unmet needs in cardiovascular risk reduction, highlighting the role of emerging therapies such as bempedoic acid, inclisiran, and gene editing technologies.

Video: Exploring Bempedoic Acid: Clinical Indications, Efficacy, and Future Directions in Cardiovascular Risk Management

ByPam R. Taub, MD, FACC, FASPC ,Marc P. Bonaca, MD, MPH

December 17th 2024

Panelists discuss how bempedoic acid offers a promising alternative for patients who are statin-intolerant, demonstrating efficacy in reducing major cardiovascular events and low-density lipoprotein cholesterol, while addressing its role in managing residual cardiovascular risk, particularly in high-risk populations.

Exploring Bempedoic Acid: Clinical Indications, Efficacy, and Future Directions in Cardiovascular Risk Management

ByPam R. Taub, MD, FACC, FASPC ,Marc P. Bonaca, MD, MPH

December 13th 2024

Concluding Thoughts

ByDeepak Bhatt, MD, MPH,Marc P. Bonaca, MD, MPH,Sahil Parikh, MD,Eric Secemsky, MD,Amy Pollak, MD,Manesh Patel, MD

June 10th 2022

A panel of expert cardiologists share their concluding thoughts on management of polyvascular disease in clinical practice.

Unmet Needs and Emerging Approaches to Management of Polyvascular Disease

ByDeepak Bhatt, MD, MPH,Marc P. Bonaca, MD, MPH,Sahil Parikh, MD,Eric Secemsky, MD,Amy Pollak, MD,Manesh Patel, MD

June 10th 2022

Cardiologists share unmet needs and emerging approaches to management of patients with polyvascular disease.

VOYAGER Trial and DPI in Clinical Practice

ByDeepak Bhatt, MD, MPH,Marc P. Bonaca, MD, MPH,Sahil Parikh, MD,Eric Secemsky, MD,Amy Pollak, MD,Manesh Patel, MD

June 10th 2022

Manesh Patel, MD, reviews VOYAGER trial data and expert cardiologists share where they use DPI [dual pathway inhibition] in their practices.

COMPASS Trial for CAD and PAD

ByDeepak Bhatt, MD, MPH,Marc P. Bonaca, MD, MPH,Sahil Parikh, MD,Eric Secemsky, MD,Amy Pollak, MD,Manesh Patel, MD

June 3rd 2022

Expert cardiologists discuss data from COMPASS trial and the role of rivaroxaban and low-dose aspirin in treatment of patients with CAD and PAD.

Access to and Awareness of DPI for Polyvascular Disease

ByDeepak Bhatt, MD, MPH,Marc P. Bonaca, MD, MPH,Sahil Parikh, MD,Eric Secemsky, MD,Amy Pollak, MD,Manesh Patel, MD

June 3rd 2022

Sahil Parikh, MD, shares how lack of access to or awareness of DPI [dual pathway inhibition] causes many practices and health care providers to face a challenge in treating CAD [coronary artery disease].

Direct Oral Anticoagulants and Dosing

ByDeepak Bhatt, MD, MPH,Marc P. Bonaca, MD, MPH,Sahil Parikh, MD,Eric Secemsky, MD,Amy Pollak, MD,Manesh Patel, MD

May 27th 2022

Drs Patel and Bhatt discuss importance of correct dosing of direct oral anticoagulants in treatment of cardiovascular diseases.

Dual Pathway Inhibition in Coronary Artery Disease

ByDeepak Bhatt, MD, MPH,Marc P. Bonaca, MD, MPH,Sahil Parikh, MD,Eric Secemsky, MD,Amy Pollak, MD,Manesh Patel, MD

May 27th 2022

Expert cardiologists provide an overview of dual pathway inhibition, modulation of thrombotic risk and treatment of CAD.

Risk-Benefit Analysis in Treatment Selection in CAD

ByDeepak Bhatt, MD, MPH,Marc P. Bonaca, MD, MPH,Sahil Parikh, MD,Eric Secemsky, MD,Amy Pollak, MD,Manesh Patel, MD

May 20th 2022

Dr Amy Pollak shares her thoughts on risk-benefit analysis when evaluating patients with high thrombotic/bleeding risk and treatment selection.

Stents in Treatment of CAD and PAD

ByDeepak Bhatt, MD, MPH,Marc P. Bonaca, MD, MPH,Sahil Parikh, MD,Eric Secemsky, MD,Amy Pollak, MD,Manesh Patel, MD

May 20th 2022

Dr Eric Secemsky discusses how use of stents has evolved over the years in treatment of polyvascular disease.

Dual Antiplatelet Therapy in CAD

ByDeepak Bhatt, MD, MPH,Marc P. Bonaca, MD, MPH,Sahil Parikh, MD,Eric Secemsky, MD,Amy Pollak, MD,Manesh Patel, MD

May 13th 2022

Dr Manesh Patel and other experts discuss the role of dual antiplatelet therapy (DAPT) in treatment of coronary artery disease.

Regimen Intensification in Polyvascular Disease

ByDeepak Bhatt, MD, MPH,Marc P. Bonaca, MD, MPH,Sahil Parikh, MD,Eric Secemsky, MD,Amy Pollak, MD,Manesh Patel, MD

May 13th 2022

Drs Marc Bonaca and Deepak Bhatt discuss the role of therapy intensification when managing high-risk patients with polyvascular disease.

Guidelines and Management of Patients With Polyvascular Disease

ByDeepak Bhatt, MD, MPH,Marc P. Bonaca, MD, MPH,Sahil Parikh, MD,Eric Secemsky, MD,Amy Pollak, MD,Manesh Patel, MD

May 6th 2022

Expert cardiologists discuss CAD guidelines and approaches to management of patients with polyvascular disease.

Provider Engagement and Screening

ByDeepak Bhatt, MD, MPH,Marc P. Bonaca, MD, MPH,Sahil Parikh, MD,Eric Secemsky, MD,Amy Pollak, MD,Manesh Patel, MD

May 6th 2022

Dr Sahil Parikh and other experts discuss engagement of cardiologists in patients diagnosed with polyvascular disease and challenges in screening patients.